BioNTech completes phase-II trial of COVID-19 vaccine in China
The vaccine, based on messenger RNA (mRNA) technology, is one of the most widely used worldwide against COVID, but has yet to receive an approval in China, which has relied only on domestically-developed vaccine
BioNTech completed a phase-II clinical trial of its COVID-19 vaccine in China in January but has yet to release its results, a registry of such trials showed yesterday.
The vaccine, based on messenger RNA (mRNA) technology, is one of the most widely used worldwide against COVID, but has yet to receive an approval in China, which has relied only on domestically-developed vaccine.
China’s leading medical experts have urged authorities to retain tough zero-COVID measures so as to buy time and step up vaccination rates and develop new treatments, in the battle on the country’ biggest outbreak.
The phase-II trial on the vaccine’s safety and immunogenicity began in late 2020, according to a database managed by an agency under the US National Institutes of Health (NIH).
Edits by EP News Bureau
- Advertisement -